The Technical Analyst
Novartis AG [NVS]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—General
Novartis AG Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.54% $99.60
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 194 866 mill |
| EPS: | 4.40 |
| P/E: | 22.64 |
| Earnings Date: | Jul 16, 2024 |
| SharesOutstanding: | 1 956.49 mill |
| Avg Daily Volume: | 1.608 mill |
| RATING 2024-05-08 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.47x |
| Company: PE 22.64 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.94x |
| Company: PE 22.64 | industry: PE 24.13 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$98.26 (-1.35%) $-1.344 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 98.31 - 100.89 ( +/- 1.30%) |
| ATR Model: 14 days |
Forecast:
16:00 - $99.62
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $99.62
Forecast 2: 16:00 - $99.62
Forecast 3: 16:00 - $99.62
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $99.60 (0.54% ) |
| Volume | 1.008 mill |
| Avg. Vol. | 1.608 mill |
| % of Avg. Vol | 62.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest Press Releases
2024-05-07 09:12:00 - Press Release
Cagent Vascular Appoints Chairman Brian Walsh To Expanded Role As Chief Executive Officer
Wayne, pa.--(business wire)-- #cli--cagent vascular announced today that brian walsh has been named chief executive officer by the cagent vascular board of directors. he has served as chairman of the board since march 2018 and will continue in this capacity. mr. walsh will succeed carol burns as ceo. mr. walsh previously served as head of carl zeiss meditech cataract technology from 2018 until 2024. prior to that, he was president and ceo of iantech medical, inc. (acquired by carl zeiss meditech ag) a.
2024-04-30 07:00:00 - Press Release
Peptidream Announces Expansion Of Peptide Discovery Collaboration With Novartis
Kawasaki, japan--(business wire)--peptidream inc., a public kanagawa, japan-based biopharmaceutical company (president and ceo: patrick c. reid, hereinafter “peptidream”) (tokyo: 4587) today announced an expansion of its peptide discovery collaboration with swiss-based novartis pharma ag (“hereinafter novartis”) (nyse: nvs). under the multi-program agreement, peptidream will use its proprietary peptide discovery platform system (“pdps®”) technology to identify and optimize novel macrocyclic pep.
2024-04-24 00:30:00 - Press Release
Novartis And Medicines For Malaria Venture Announce Positive Efficacy And Safety Data For A Novel Treatment For Babies
Basel, april 24, 2024 – novartis and medicines for malaria venture (mmv) announce positive data from their phase ii/iii calina study, demonstrating that a novel formulation of coartem® (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety. the trial was conducted in several african countries. the data, which will be presented this week at the multilateral initiative on malaria (mim society) 8th pan-african malaria conference in kigali, have been submitted for regulatory review.
2024-04-23 13:42:00 - Press Release
Novartis Radioligand Therapy Lutathera® Fda Approved As First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Basel, april 23, 2024 – novartis today announced that the u.s. food and drug administration (fda) approved lutathera® (usan: lutetium lu 177 dotatate / inn: lutetium (177lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (sstr+) gastroenteropancreatic neuroendocrine tumors (gep-nets), including foregut, midgut, and hindgut nets. this approval makes lutathera the first therapy specifically reviewed and approved for use in pediatric patients with gep-nets.
2024-04-23 01:00:00 - Press Release
Novartis Delivers Double-digit Sales Growth And Core Margin Expansion In Q1; Fy 2024 Guidance Raised
Ad hoc announcement pursuant to art. 53 lr q1 net sales grew +11% (cc 1 , +10% usd) with core operating income up +22% (cc, +16% usd) key growth drivers continued strong sales momentum including entresto (+36% cc), cosentyx (+25% cc), kesimpta (+66% cc), kisqali (+54% cc), pluvicto (+47% cc) and leqvio (+139% cc) core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net sales operating income grew +39% (cc, +29% usd) and net income grew +37% (cc, +25% usd), mainly driven by higher net sales core eps grew +23% (cc, +17% usd) to usd 1.80 free cash flow 1 usd 2.0 billion (-24% usd) declined due to a prior-year one-timer and timing of payments q1 selected innovation milestones: fabhalta (iptacopan) fda filing accepted for igan and positive chmp opinion for pnh scemblix phase iii asc4first study met both primary endpoints in 1l ph+ cml-cp patients pluvicto phase iii psmafore updated os results demonstrated hr
Latest News
2024-05-05 14:25:00 - The Motley Fool
2 Magnificent Dividend Stocks to Hold for the Next Decade
Novartis has increased its payout for 27 consecutive years thanks to a robust, innovation-driven business. Visa is an undisputed leader in its niche and still has strong growth prospects.
2024-05-02 07:18:48 - Reuters
Novartis to buy radiology specialist Mariana Oncology for $1 billion
Novartis has entered an agreement to acquire US radiopharmaceutical company Mariana Oncology for $1 billion, the Swiss drug manufacturer said on Thursday.
2024-05-02 07:18:00 - Market Watch
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
2024-04-30 20:36:07 - Seeking Alpha
MorphoSys: Hold Rating Until The Novartis Deal Closes
MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals received and successful precedents of similar M&A transactions. Pelabresib, MorphoSys's leading candidate for myelofibrosis treatment, shows promising results and potential as a game-changer in the field.
2024-04-29 05:11:46 - Reuters
Morphosys says Novartis takeover progressing as planned for H1 2024
Morphosys said its takeover by Novartis was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price on Monday.
2024-04-27 07:00:00 - Seeking Alpha
16 High-Yield Dividend Aristocrats Yielding Almost 5%
Attempting to time the market is not a successful strategy. Long-term investing has consistently outperformed market timing. Today, the S&P is fairly valued, but blue-chip bargains are plentiful if you know where to look. These 16 dividend aristocrats yield an average of 4.7%, are 18% undervalued, have 30% 12-month upside potential, and are expected to keep delivering 12% to 13% annual returns just as they have for 25 years.
2024-04-23 18:25:09 - The Motley Fool
Why Novartis Stock Topped the Market on Tuesday
The pharmaceutical sector mainstay posted its first-quarter results. It beat on both the top and bottom lines.
2024-04-23 14:10:58 - Proactive Investors
Novartis raises full-year sales and profit guidance after strong Q1
Novartis AG (ADR) (NYSE:NVS) has raised its full-year revenue and profit guidance following a strong first quarter driven by momentum in key products including psoriasis drug Cosentyx, relapsing Multiple Sclerosis medicine Kesimipta and high cholesterol drug Leqvio. The Swiss drugmaker expects its 2024 sales to grow in the high-single to low-double-digit percentage range, compared to its earlier expectation of a mid-single-digit increase.
2024-04-23 13:39:35 - CNBC Television
Novartis CEO: Here's why we boosted our full-year guidance
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.
2024-04-23 12:30:45 - Investopedia
Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb
American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and boosted its guidance on strong demand for its top-selling drugs, Entresto and Cosentyx.